Oral anti-cancer agent Teysuno gets European marketing authorization
The EC’s marketing authorization decision was based in part on the results of the First-Line Advanced Gastric Cancer Study (FLAGS), an international Phase III trial conducted in patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.